## Supplemental Digital Content 4. Sociodemographic characteristics by health condition in 2019

|   | n | prevalencee (%) | women (%) | median age (IQR) | social precarityf (%) |
| --- | --- | --- | --- | --- | --- |
| Whole population | 66 266 685 | 100 | 52 | 42 (21-61) | 9·1 |
| No health condition identified | 36 194 044 | 55 | 50 | 29 (14-46) | 9·5 |
| Cardiovascular diseases and chronic treatments | 13 605 415 | 21 | 52 | 70 (60-79) | 3·9 |
|  Acute coronary syndrome | 103 648 | 0·16 | 32 | 70 (59-81) | 6·3 |
|  Chronic coronary disease without acute event | 1 983 957 | 3·0 | 30 | 73 (64-82) | 3·6 |
|  Acute stroke | 124 733 | 0·19 | 48 | 77 (65-86) | 4·9 |
|  Sequelae of stroke | 833 164 | 1·3 | 48 | 74 (63-84) | 4·1 |
|  Acute heart failure | 197 856 | 0·30 | 50 | 84 (75-90) | 2·7 |
|  Chronic heart failure without acute event | 662 875 | 1·0 | 50 | 82 (71-89) | 3·1 |
|  Peripheral vascular diseases | 714 256 | 1·1 | 33 | 73 (65-83) | 4·0 |
|  Heart arrhythmia or conduction disorders | 1 785 941 | 2·7 | 46 | 79 (69-86) | 2·4 |
|  Valvular heart diseases | 461 016 | 0·70 | 47 | 78 (68-86) | 2·9 |
|  Pulmonary embolism | 44 805 | 0·068 | 52 | 72 (60-83) | 5·3 |
|  Other cardiovascular diseases | 351 056 | 0·53 | 40 | 70 (57-81) | 4·8 |
|  Antihypertensive treatmentsa | 7 329 506 | 11 | 59 | 68 (58-77) | 4·0 |
|  Lipid-lowering treatmentsa | 3 056 830 | 4·6 | 55 | 69 (61-77) | 2·8 |
| Diabetes | 3 964 561 | 6·0 | 45 | 69 (60-77) | 6·7 |
| Cancers | 3 297 155 | 5·0 | 52 | 71 (61-80) | 3·3 |
|  Active female breast cancer | 228 165 | 0·66 | 100 | 64 (53-74) | 4·7 |
|  Follow-up for female breast cancer | 495 965 | 1·43 | 100 | 70 (60-78) | 2·3 |
|  Active colorectal cancer | 150 434 | 0·23 | 44 | 71 (63-80) | 3·8 |
|  Follow-up for colorectal cancer | 220 811 | 0·33 | 48 | 74 (66-83) | 1·9 |
|  Active lung cancer | 98 603 | 0·15 | 37 | 68 (61-75) | 5·9 |
|  Follow-up for lung cancer | 54 018 | 0·082 | 37 | 70 (63-77) | 3·1 |
|  Active prostate cancer | 220 797 | 0·70 | 0 | 73 (67-81) | 2·3 |
|  Follow-up for prostate cancer | 314 728 | 0·99 | 0 | 75 (70-82) | 1·1 |
|  Other active cancers | 836 056 | 1·3 | 46 | 70 (59-80) | 4·4 |
|  Follow-up for other cancers | 934 542 | 1·4 | 52 | 70 (58-81) | 3·2 |
| Psychiatric diseases and chronic treatments | 8 103 919 | 12 | 62 | 62 (48-76) | 7·9 |
|  Psychotic disorders | 475 244 | 0·72 | 44 | 51 (39-63) | 11 |
|  Neurotic and mood disorders | 1 405 133 | 2·1 | 66 | 58 (46-72) | 9·0 |
|  Mental impairment | 132 039 | 0·20 | 44 | 44 (23-58) | 12 |
|  Addictive disorders | 440 883 | 0·67 | 31 | 52 (39-62) | 19 |
|  Psychiatric disorders having begun in childhood | 172 358 | 0·26 | 30 | 13 (9-19) | 24 |
|  Other psychiatric disorders | 427 305 | 0·64 | 57 | 55 (38-72) | 11 |
|  Antidepressant or mood-regulating treatmentsb | 2 994 072 | 4·5 | 69 | 61 (49-75) | 5·6 |
|  Neuroleptic treatmentsb | 325 742 | 0·49 | 53 | 64 (47-82) | 10 |
|  Anxiolytic treatmentsb | 3 077 668 | 4·6 | 66 | 66 (52-78) | 7·5 |
|  Hypnotic treatmentsb | 1 244 966 | 1·9 | 63 | 70 (58-80) | 6·7 |
| Neurologic diseases | 1 673 904 | 2·5 | 58 | 77 (56-87) | 4·6 |
|  Dementia (including Alzheimer disease) | 760 673 | 1·1 | 68 | 86 (81-91) | 1·2 |
|  Parkinson disease | 271 583 | 0·41 | 49 | 79 (71-85) | 1·7 |
|  Multiple sclerosis | 115 498 | 0·17 | 72 | 52 (41-62) | 4·9 |
|  Paraplegia | 97 635 | 0·15 | 43 | 56 (41-69) | 7·0 |
|  Myopathy or myasthenia | 48 334 | 0·073 | 50 | 54 (36-69) | 6·8 |
|  Epilepsy | 342 385 | 0·52 | 47 | 51 (29-69) | 12 |
|  Other neurologic conditions | 175 486 | 0·26 | 49 | 55 (34-70) | 7·2 |
| Chronic respiratory diseasesc | 3 656 804 | 5·5 | 50 | 59 (33-72) | 10 |
| Chronic inflammatory diseases | 964 753 | 1·5 | 62 | 59 (45-72) | 5·4 |
|  Inflammatory bowel diseases | 273 098 | 0·41 | 53 | 49 (36-63) | 6·4 |
|  Rheumatoid arthritis and related diseases | 299 918 | 0·45 | 72 | 67 (55-77) | 4·3 |
|  Ankylosing spondylitis and related diseases | 228 949 | 0·35 | 52 | 54 (43-66) | 5·7 |
|  Other chronic inflammatory diseases | 215 598 | 0·33 | 73 | 66 (51-78) | 5·4 |
| Rare diseases | 180 599 | 0·27 | 47 | 57 (35-71) | 6·6 |
|  Hereditary metabolic diseases or amyloidosis | 120 196 | 0·18 | 46 | 59 (38-72) | 6·3 |
|  Cystic fibrosis | 8 796 | 0·013 | 48 | 24 (13-38) | 9·7 |
|  Hemophilia or severe hemostasis disorders | 52 021 | 0·079 | 51 | 55 (38-70) | 6·6 |
| HIV infection | 151 346 | 0·23 | 33 | 51 (42-58) | 15 |
| End-stage renal disease | 98 427 | 0·15 | 38 | 66 (54-76) | 6·8 |
|  Chronic dialysis | 54 566 | 0·082 | 39 | 72 (62-81) | 6·5 |
|  Kidney transplant | 3 514 | 0·0053 | 38 | 56 (44-67) | 10 |
|  Follow-up for kidney transplant | 40 347 | 0·061 | 38 | 59 (47-68) | 6·9 |
| Liver or pancreas diseasesc | 604 162 | 0·91 | 43 | 61 (50-72) | 11 |
| Other long term diseases | 1 975 489 | 3·0 | 56 | 65 (43-79) | 7 |
| Maternity | 1 265 621 | 3·7 | 100 | 31 (28-35) | 18 |
| Hospitalisation for other reasons | 9 417 185 | 14 | 53 | 55 (31-71) | 8·7 |
| Analgesic or NSAI treatmentd | 1 308 126 | 2·0 | 62 | 35 (5-51) | 24 |

Abbreviations: NSAI, non-steroidal anti-inflammatory; IQR, interquartile range

a without a diagnosis of cardiovascular disease, diabetes or end-stage renal disease. b without a diagnosis of mental illness. c excluding cystic fibrosis. d excluding diseases, treatments, maternity care or hospitalisation. e among men or women only when appropriate. f complementary universal health insurance beneficiaries